10x Insights
Loading account…
TCAF

T. Rowe Price Capital Appreciation Equity ETF

Actively managedEquityETF
T. Rowe Price Exchange-Traded Funds, Inc.: TCAFHoldings as of Jun 30, 2026Filed Aug 27, 2026

Actively managed U.S. stock ETF

As of its 2026 Q2 report, T. Rowe Price Capital Appreciation Equity ETF held 92 positions with $7.40B in net assets. Its ten largest holdings made up 40.9% of the fund. The TCAF share class costs 0.31% a year. Over the 12 months to May 2026, TCAF returned 23.2%, with dividends reinvested. In 2026 Q2 it added 18 new positions and exited 19.

2026 Q2 holdings and allocationChanges are against the previous quarter, 2026 Q1Headline fees and returns use the TCAF share class
Expense ratio · TCAF
0.31%
$31 a year for every $10,000 invested
one share class
$7.40B
The whole fund, all share classes
92 holdings
40.9%in the top 10
Weight held in the ten largest holdings
Top 25 hold 66.9%
Return, 1 year · TCAF
+23.2%
With dividends, to May 2026
3 yr total +66.5%
What this fund is
Objective, as filed

The fund seeks to provide long-term capital growth.

Strategy, summarised

The fund invests at least 80% of its net assets in equity securities, selecting stocks through bottom-up analysis of individual companies rather than macroeconomic forecasting. The adviser evaluates management quality, risk-adjusted return potential, market position, and valuation, with a core approach that does not emphasize growth or value style; the fund typically focuses on large U.S. companies but may purchase stocks of any size. The fund is nondiversified, meaning it may invest a greater percentage of its assets in a particular issuer than is permissible for a diversified fund. Because sector allocations result largely from individual stock selection rather than sector strategy, the fund may at times hold a significant portion of assets in a single economic sector.

What you own

per cent of the fund
CompanyWeightValue
5.83%
$431.30M
5.30%
$392.41M
5.14%
$380.25M
4.70%
$348.10M
4.36%
$322.57M
4.18%
$309.08M
3.14%
$232.64M
3.03%
$224.39M
2.65%
$196.31M
2.60%
$192.70M
Showing 1–10 of 92 · the top 10 are 40.94% of the fund, the top 25 are 66.93%

Reported price is the fund's own reported value divided by its own reported shares at 2026-06-30 — not a live quote, and not what the fund paid.

All 92 holdings, with the share counts as filed, open with a free account.

What the fund is made of

Percentages are of fund net assets. Rounding, liabilities and short positions can make totals differ from 100%.

99.96%
of net assets
Stocks99.84%
Cash & short-term0.12%

By sector

Information Technology
28.6%
Health Care
16.1%
Consumer Discretionary
10.1%
Communication Services
10.1%
8 other sectors
35.1%

How it has done

Total return, dividends reinvested · to May 2026

TCAF share class · total returns with dividends reinvested

1 year
+23.18%
3 years
+66.47%
Cumulative, not per year
5 years
—
Cumulative, not per year
36 of 60 months
Largest decline in 3 years
-7.91%
From a previous high to a later low
Cumulative return, last three years· Jul 2023 – May 2026

Volatility over the last 12 months: 14.02%. Past returns are a record, not a forecast.

Jun 2026 has been filed since the trailing figures were struck, so it is not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.

Fees & fund details

T. Rowe Price Capital Appreciation Equity ETF is an actively managed U.S. equity ETF. 18% of TCAF’s stock holdings are in companies whose revenue grew in the top quartile of U.S. companies over the last five fiscal years (covering 92% of the fund’s equity).

Asset class
Equity
Region
United States
Management
Actively managed
Fund type
ETF
Features
Non-diversified
Expense ratio, by class
0.31%· TCAF 0.31%
Portfolio turnover
29.30% a year · as of 2026 Q1

Turnover is how much of the portfolio was replaced in a year.

Classified from what the fund holds, not from its name · 2026 Q2. The summary is a paraphrase of the prospectus; the objective is verbatim.

What changed this quarter

2026 Q2 vs 2026 Q1

Positions that entered or left the fund since its previous filing. Positions that were only resized are not listed.

18 new· the largest 8

19 exited· the largest 8

ASCENDIS PHARMA A/S - ADR
BIONTECH SE-ADR
SAP SE SPONSORED ADRSAP

Debt profile

What this fund holds — value-weighted across its bond and securitized long positions · as of 2026-06-30

Avg coupon
—
Avg maturity
—
Flagged holdings
Defaulted: not reported
In arrears: not reported
Paid in kind: not reported

Based on what filers reported; a filer that never reported a flag also reads as none.

Risk profile

Interest-rate and credit-spread sensitivity, both in years · as of 2026Q2

This fund filed the credit-spread disclosure and reported no sensitivity — measured, and the answer is none.

0.00 yr
approx. move per 100bp
0.00 yr
approx. move per 100bp
Investment grade: +0.00 yrHigh yield: +0.00 yr
Show the numbers
TenorRate yrsIG yrsHY yrsIG $/bpHY $/bp
3 mo+0.00+0.00+0.00$0$0
1 yr+0.00+0.00+0.00$0$0
5 yr+0.00+0.00+0.00$0$0
10 yr+0.00+0.00+0.00$0$0
30 yr+0.00+0.00+0.00$0$0

Dollar change per 1bp of spread movement, as filed and sign-anchored. A blank cell was not filed; a zero was.

Connected research

Understand how this fund fits with the rest.

Explore shared holdings, compare funds and follow their businesses with your connected AI:

  • “Where do my funds overlap — TCAF, QQQ and the fund in my 401(k)?”
  • “How do this fund’s ten biggest holdings stack up against each other?”
  • “For my target-date fund, what’s the real stock-and-bond mix once you look through it?”
See how it works →All research tools with a subscription. Use your own AI account.